(-0.12%) 5 140.75 points
(-0.11%) 38 517 points
(-0.03%) 17 899 points
(-0.25%) $82.42
(1.72%) $2.07
(-0.89%) $2 336.80
(-1.90%) $27.14
(-0.40%) $957.70
(0.20%) $0.934
(0.39%) $11.03
(0.16%) $0.797
(0.01%) $93.31
@ $11.85
Išleistas: 14 vas. 2024 @ 20:14
Grąža: -18.73%
Ankstesnis signalas: vas. 13 - 19:38
Ankstesnis signalas:
Grąža: 1.28 %
Live Chart Being Loaded With Signals
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK...
Stats | |
---|---|
Šios dienos apimtis | 39 493.00 |
Vidutinė apimtis | 143 859 |
Rinkos kapitalizacija | 243.60M |
EPS | $0 ( 2024-03-12 ) |
Kita pelno data | ( $-1.160 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.43 |
ATR14 | $0.0400 (0.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Calkins Daniel | Sell | 6 | Common Stock |
2024-03-25 | Calkins Daniel | Sell | 25 | Common Stock |
2024-03-20 | Calkins Daniel | Sell | 55 | Common Stock |
2024-03-18 | Gagnon Robert E. | Sell | 283 | Common Stock |
2024-03-19 | Gagnon Robert E. | Sell | 130 | Common Stock |
INSIDER POWER |
---|
50.15 |
Last 99 transactions |
Buy: 1 037 036 | Sell: 241 539 |
Tūris Koreliacija
Verastem Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
PXLW | 0.908 |
CVCY | 0.885 |
IMAB | 0.884 |
SRRK | 0.882 |
ADXN | 0.88 |
SHYF | 0.875 |
FOXA | 0.872 |
VIRC | 0.863 |
CRTO | 0.863 |
FLUX | 0.86 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Verastem Inc Koreliacija - Valiuta/Žaliavos
Verastem Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-62 000.00 (0.00 %) |
EPS: | $-3.96 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-62 000.00 (0.00 %) |
EPS: | $-3.96 |
FY | 2022 |
Pajamos: | $2.60M |
Bruto pelnas: | $2.48M (95.45 %) |
EPS: | $-4.58 |
FY | 2021 |
Pajamos: | $2.05M |
Bruto pelnas: | $2.05M (100.00 %) |
EPS: | $-0.464 |
Financial Reports:
No articles found.
Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.